niacinamide has been researched along with olmesartan in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abd-Alhaseeb, MM; Abou-El-Ela, SH; Moustafa, YM; Zaitone, SA | 1 |
Beloborodov, VA; Borisova, VM; Golub, IY; Kur'yanov, AA; Sorokina, LV | 1 |
1 trial(s) available for niacinamide and olmesartan
Article | Year |
---|---|
[COGNITIVE ABNORMALITIES IN POSTOPERATIVE PERIOD OF THYROID SURGERY].
Topics: Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Drug Combinations; Female; Flavin Mononucleotide; Follow-Up Studies; Humans; Hyperparathyroidism; Imidazoles; Inosine Diphosphate; Niacinamide; Postoperative Complications; Prognosis; Prospective Studies; Succinates; Tetrazoles; Thyroidectomy | 2015 |
1 other study(ies) available for niacinamide and olmesartan
Article | Year |
---|---|
Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7).
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Female; Imidazoles; Immunohistochemistry; Insulin-Like Growth Factor I; Mice; Neovascularization, Pathologic; Niacinamide; Peptide Fragments; Phenylurea Compounds; Receptor, IGF Type 1; Sorafenib; Tetrazoles; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |